---
title: "Johnson & Johnson Advances Cancer and Immunology Treatments With Major Biotech Deals"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294389194.md"
description: "Johnson & Johnson is expanding its biotech pipeline through two major deals: a $1 billion acquisition of Firefly Bio to integrate its solid tumor targeting platform, and a strategic partnership with Sail Biomedicines for in vivo CAR-T therapies. The Sail deal includes $785 million upfront and an option to acquire the company for $2.58 billion. These transactions are expected to impact JNJ's adjusted earnings per share in 2026 and 2027."
datetime: "2026-07-30T15:31:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294389194.md)
  - [en](https://longbridge.com/en/news/294389194.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294389194.md)
generator: "portal-rs"
---

# Johnson & Johnson Advances Cancer and Immunology Treatments With Major Biotech Deals

**Johnson & Johnson** (NYSE:JNJ) is significantly expanding its biotechnology portfolio with two major deals, securing a $1 billion acquisition of **Firefly Bio Inc**. and forging a strategic partnership with S**ail Biomedicines** that includes an option to purchase the latter for $2.58 billion.

## **Targeting Solid Tumors With Firefly Bio**

The healthcare giant successfully finalized its $1 billion cash purchase of Firefly Bio, earlier announced in June. The strategic move integrates the proprietary Firelink degrader antibody conjugate platform into the company’s oncology pipeline.

The technology addresses a major unmet medical need by targeting challenging solid tumors, including KRAS-driven cancers.

It functions by delivering highly selective protein degraders straight to cancer cells while protecting healthy tissue, overcoming a primary limitation of existing treatments.

The buyout will trigger an in-process research and development charge of approximately $1 billion during the third quarter of 2026.

 **Read Also: Johnson & Johnson Puts 15-Year Meritless Talc Litigation To Rest** 

Consequently, the transaction is projected to reduce adjusted earnings per share by roughly $0.46 in 2026 and $0.08 in 2027.

## **Pioneering CAR-T Therapies With Sail Biomedicines**

The pharmaceutical leader on Thursday revealed a collaboration with Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated conditions.

Building on its established expertise in immunology and oncology, this partnership aims to advance curative treatment approaches.

Unlike conventional cell treatments, Sail’s platform is designed to reprogram a patient’s immune cells directly inside the body. This innovative approach seeks to reset the immune system and deliver durable disease control.

The agreement involves $785 million in upfront payments, which includes a $465 million equity stake, alongside $140 million tied to specific development milestones.

Furthermore, the firm secured an exclusive right to acquire Sail for an additional $2.58 billion.

If executed, this buyout would dilute adjusted operational earnings per share by about $0.18 in 2026 and $1.28 in 2027.

**JNJ Price Action:** Johnson & Johnson shares were down 3.63% at $255.88 at the time of publication on Thursday, according to Benzinga Pro data.

*Image via Shutterstock*

 **Read Also: Adam Schiff Hits Sable Offshore Over Oil Spill Risk, Then Blasts Trump's Washington Airport Makeover as Gas Prices Climb: 'Cost Is No Object…'**

### Related Stocks

- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [SOC.US](https://longbridge.com/en/quote/SOC.US.md)

## Related News & Research

- [Johnson & Johnson names new vice president for litigation](https://longbridge.com/en/news/296647636.md)
- [Three scientists beat J&J's defamation suit over talc research](https://longbridge.com/en/news/296638678.md)
- [Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference | ANIX Stock News](https://longbridge.com/en/news/296231345.md)
- [Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet.](https://longbridge.com/en/news/296643850.md)
- [J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B](https://longbridge.com/en/news/294502666.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**